5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits

Despite marked tumor shrinkage after 5-FU treatment, the frequency of colon cancer relapse indicates that a fraction of tumor cells survives treatment causing tumor recurrence. The majority of cancer cells divert metabolites into anabolic pathways through Warburg behavior giving an advantage in terms of tumor growth. Here, we report that treatment of colon cancer cell with 5-FU selects for cells with mesenchymal stem-like properties that undergo a metabolic reprogramming resulting in addiction to OXPHOS to meet energy demands. 5-FU treatment-resistant cells show a de novo expression of pyruvate kinase M1 (PKM1) and repression of PKM2, correlating with repression of the pentose phosphate pathway, decrease in NADPH level and in antioxidant defenses, promoting PKM2 oxidation and acquisition of stem-like phenotype. Response to 5-FU in a xenotransplantation model of human colon cancer confirms activation of mitochondrial function. Combined treatment with 5-FU and a pharmacological inhibitor of OXPHOS abolished the spherogenic potential of colon cancer cells and diminished the expression of stem-like markers. These findings suggest that inhibition of OXPHOS in combination with 5-FU is a rational combination strategy to achieve durable treatment response in colon cancer.

[1]  J. Koster,et al.  SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer , 2015, Clinical Cancer Research.

[2]  A. Mitsuhashi,et al.  Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. , 2015, Oncology reports.

[3]  D. Wolf.  Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer? , 2014, Cancer cell.

[4]  F. Sotgia,et al.  Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition , 2014, Oncotarget.

[5]  R. Kalluri,et al.  Corrigendum: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis , 2014, Nature Cell Biology.

[6]  Eva M. Schmelz,et al.  Ovarian tumor-initiating cells display a flexible metabolism. , 2014, Experimental cell research.

[7]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[8]  T. Copetti,et al.  A mitochondrial switch promotes tumor metastasis. , 2014, Cell reports.

[9]  N. Hay,et al.  The pentose phosphate pathway and cancer. , 2014, Trends in biochemical sciences.

[10]  K. Struhl,et al.  Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[11]  Y. Song,et al.  Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer , 2014, BioMed research international.

[12]  B. Bao,et al.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. , 2014, Annals of translational medicine.

[13]  Liming Wang,et al.  Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. , 2014, Oncology reports.

[14]  J. Ajani,et al.  Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer , 2014, International journal of oncology.

[15]  P. Nangia-Makker,et al.  Metformin: A Potential Therapeutic Agent for Recurrent Colon Cancer , 2014, PloS one.

[16]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[17]  W. ElShamy,et al.  Overview: cellular plasticity, cancer stem cells and metastasis. , 2013, Cancer letters.

[18]  M. Hidalgo,et al.  Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells , 2013, PloS one.

[19]  A. Iwama,et al.  Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line , 2013, International journal of oncology.

[20]  Sung Soo Kim,et al.  Cancer cell metabolism: implications for therapeutic targets , 2013, Experimental & Molecular Medicine.

[21]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[22]  Erika Martinelli,et al.  Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines , 2013, Clinical Cancer Research.

[23]  P. Puigserver,et al.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.

[24]  Shicai Chen,et al.  CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[25]  M. Mimeault,et al.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells , 2013, Journal of cellular and molecular medicine.

[26]  G. Sambuceti,et al.  Metformin selectively affects human glioblastoma tumor-initiating cell viability , 2013, Cell Cycle.

[27]  J. van Rheenen,et al.  Brief Report: Intravital Imaging of Cancer Stem Cell Plasticity in Mammary Tumors , 2012, Stem cells.

[28]  J. Lancaster,et al.  Integration of cellular bioenergetics with mitochondrial quality control and autophagy , 2012, Biological chemistry.

[29]  W. Marston Linehan,et al.  Targeting Cancer Metabolism , 2012, Clinical Cancer Research.

[30]  A. Munkarah,et al.  Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis , 2012, Journal of oncology.

[31]  Chunxiao Zhou,et al.  Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. , 2012, Gynecologic oncology.

[32]  D. Tang,et al.  Understanding cancer stem cell heterogeneity and plasticity , 2012, Cell Research.

[33]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[34]  E. Giannoni,et al.  Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. , 2011, Antioxidants & redox signaling.

[35]  R. McLendon,et al.  Acidic stress promotes a glioma stem cell phenotype , 2011, Cell Death and Differentiation.

[36]  N. Suzuki,et al.  Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. , 2011, Experimental and therapeutic medicine.

[37]  Kevin Struhl,et al.  Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. , 2011, Cancer research.

[38]  A. Goldkorn,et al.  Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype , 2011, Molecular Cancer Therapeutics.

[39]  J. Sarkaria,et al.  Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain* , 2010, The Journal of Biological Chemistry.

[40]  V. Darley-Usmar,et al.  Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. , 2010, Free radical biology & medicine.

[41]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[42]  Paul Salama,et al.  Colorectal cancer stem cells , 2009, ANZ journal of surgery.

[43]  F. Esposito,et al.  TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. , 2009, Cancer letters.

[44]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[45]  M. Andreeff,et al.  Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. , 2009, Cancer research.

[46]  Giampaolo Manao,et al.  Proliferation Versus Migration in Platelet-derived Growth Factor Signaling , 2008, Journal of Biological Chemistry.

[47]  S. Lees-Miller,et al.  Doxorubicin Activates ATM-dependent Phosphorylation of Multiple Downstream Targets in Part through the Generation of Reactive Oxygen Species* , 2004, Journal of Biological Chemistry.

[48]  L. Recht,et al.  Neuropeptides and their role in nociception and analgesia. , 1986, Neurologic clinics.

[49]  Z. Xiao,et al.  ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis. , 2013, Cancer letters.

[50]  D. Cao,et al.  The origin of cancer stem cells. , 2012, Frontiers in bioscience.

[51]  M. Balañá,et al.  Metastatic cancer stem cells: new molecular targets for cancer therapy. , 2011, Current pharmaceutical biotechnology.

[52]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.